CAVA Beats Q1, But Cyclospora Fears Weigh on Outlook

Forward-Looking Analysis

Wall Street analysts forecast CAVA Group to post $0.54 earnings per share for the full current year, though specific Q2 2026 consensus estimates are not explicitly detailed in the provided data. The company reported $0.20 EPS and $438.27 million in revenue for Q1 2026, significantly beating analyst estimates of $0.17 EPS and $360.89 million in revenue. Revenue growth surged 32.1% year-over-year in Q1. Analyst sentiment remains cautiously optimistic with an average "Moderate Buy" rating and an average price target of $92.46. Recent analyst actions include Royal Bank of Canada lowering its price target from $105.00 to $90.00 while maintaining an "outperform" rating. JPMorgan Chase raised its price target from $80.00 to $90.00 with an "overweight" rating. Roth Capital reiterated a "buy" rating with a $106.00 target, while Argus set a $92.00 objective. Wall Street Zen upgraded CAVA from "sell" to "hold." Institutional ownership stands at 73.15%, with Bank of America reducing its stake by 37.6% in Q1. Conversely, Amundi increased its position by 578.4%, and EverSource Wealth Advisors raised its stake by 60.7%. Despite strong historical beats, the stock trades at a high P/E ratio of 119.86, suggesting elevated expectations for Q2 performance to justify current valuations amid broader market volatility.

CAVA Group delivered robust Q1 2026 results, reporting $438.27 million in revenue, a 32.1% increase year-over-year, and $23.57 million in net income. The company achieved a gross profit of $111.19 million and reported EPS of $0.20, surpassing consensus estimates of $0.17. Return on equity stood at 7.92% with a net margin of 4.79%, demonstrating strong operational efficiency and profitability despite a challenging macroeconomic environment.

Additional News

Insider trading activity shows Theodoros Xenohristos sold 9,044 shares at $79.75 on May 11, and Kelly Costanza sold 12,490 shares at $90.00 on June 17, both to cover tax withholding obligations. Collectively, insiders sold 91,747 shares worth $7.97 million in the last 90 days. The company faces headwinds from a cyclospora outbreak linked to iceberg lettuce, which has reduced traffic to salad chains like Chopt and Sweetgreen. While CAVA has not yet reported specific impact figures, the outbreak has caused industry-wide consumer caution regarding greens. Michigan health officials recently lifted precautionary recommendations, signaling potential recovery. CAVA’s stock opened at $62.33 recently, trading below its 50-day ($73.56) and 200-day ($76.86) moving averages, reflecting near-term market pressure.

Summary & Outlook

CAVA Group exhibits strong financial health with robust Q1 revenue growth and profitability beats. However, Q2 prospects face risks from the cyclospora outbreak impacting consumer confidence in fresh greens, potentially pressuring same-store sales. While the company maintains a "Moderate Buy" consensus with upside to the $92.46 average price target, the high valuation and recent insider selling warrant caution. The outlook is neutral-to-bearish for the immediate term due to external food safety fears, though long-term growth remains supported by aggressive expansion and institutional interest. Investors should monitor Q2 guidance for signs of recovery or continued disruption from the outbreak.